Johnson & Johnson CEO Alex Gorsky.
In difficult times such as these, we have to celebrate our wins. We had two big ones today: both the Johnson & Johnson and Novavax vaccines were found to be effective against COVID. J&J was 66% effective and Novavax 89% effective.
The FDA should approve both ASAP. Indeed, the FDA is considering authorizing the Novavax vaccine based on data from overseas. J&J is likely to be authorized in February. Since many are dying each day, each day of delay is very costly.
Both were less effective against the variant from South Africa, with Novavax below 50% efficacy there. But Novavax is working on a new formulation to counter that variant.
We face a constrained supply of vaccines, so any effective ones we can add to our toolkit are a huge win!